Cyclacel pharmaceuticals to present new clinical data from phase 2 study of oral fadraciclib at the 2024 eortc-nci-aacr symposium

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for cdkn2a and/or cdkn2b abnormalities

NCI Ratings Summary

NCI Quant Ranking